{
    "clinical_study": {
        "@rank": "93970", 
        "arm_group": [
            {
                "arm_group_label": "Ferrous sulfate 325mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Identical-appearing tablet taken by mouth daily for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study questions whether low-dose ferrous sulfate taken by mouth daily for 6 weeks\n      increases hemoglobin concentration in adult subjects with cystic fibrosis and hypoferremic\n      anemia."
        }, 
        "brief_title": "Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis", 
        "condition": [
            "Cystic Fibrosis", 
            "Anemia, Iron-Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Cystic Fibrosis", 
                "Fibrosis", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of Pseudomonas aeruginosa colonization of the lung\n\n          -  Transferrin saturation (TSAT) less than or equal to 21%\n\n          -  Hemoglobin concentration <15.5 gm/dl (men)\n\n          -  Hemoglobin concentration <13.6 gm/dl (women)\n\n        Exclusion Criteria:\n\n          -  Use of iron-containing vitamin or supplement\n\n          -  Pregnancy\n\n          -  Lactation\n\n          -  Cirrhosis\n\n          -  History of chronic visible (gross) hemoptysis\n\n          -  Hereditary hemochromatosis\n\n          -  History of transfusion-related iron overload\n\n          -  Use of iron chelator(s)\n\n          -  Withdrawal of informed consent\n\n          -  Contraindication to phlebotomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755455", 
            "org_study_id": "D11176", 
            "secondary_id": "CPHS#22884"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ferrous sulfate 325mg", 
                "description": "Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks", 
                "intervention_name": "Ferrous sulfate 325mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cystic fibrosis", 
            "Iron", 
            "Hepcidin", 
            "Anemia", 
            "Erythropoiesis"
        ], 
        "lastchanged_date": "December 21, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Maine", 
                        "zip": "04102"
                    }, 
                    "name": "Maine Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth-Hitchcock Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Iron Supplementation for the Hypoferremic Anemia of Cystic Fibrosis", 
        "overall_official": {
            "affiliation": "Dartmouth-Hitchcock Medical Center", 
            "last_name": "Alex H Gifford, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Hemoglobin concentration (gm/dl)", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755455"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dartmouth-Hitchcock Medical Center", 
            "investigator_full_name": "Alex H. Gifford", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum iron (mcg/dl)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Transferrin saturation (%)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Serum hepcidin-25 (ng/ml)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Serum erythropoietin (mU/ml)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Percent-predicted forced expiratory volume in one second (FEV1%)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Body weight (kg)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Akron Pulmonary Exacerbation Score (PES)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Sputum iron (ng/mg)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}